← Back to Search

Post-intervention for Systemic Inflammatory Response Syndrome

N/A
Waitlist Available
Led By Harman Gill, MD
Research Sponsored by Dartmouth-Hitchcock Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time of ed presentation to the time of in-hospital death or hospital discharge, approximately 2 weeks
Awards & highlights

Study Summary

The purpose of this study is to assess whether implementation of an ED Sepsis Tracking Sheet effects the percentage of goal-directed sepsis criteria met in a tertiary care academic Emergency Department.

Eligible Conditions
  • Systemic Inflammatory Response Syndrome
  • Sepsis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time of ed presentation to the time of in-hospital death or hospital discharge, approximately 2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and time of ed presentation to the time of in-hospital death or hospital discharge, approximately 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Septicemia
Secondary outcome measures
In-hospital mortality
Length of hospital stay

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Post-interventionExperimental Treatment1 Intervention
Patients presenting to the Emergency Department meeting severe sepsis criteria following implementation of an ED Sepsis Tracking Sheet
Group II: Pre-interventionActive Control1 Intervention
Patients presenting to the Emergency Department meeting severe sepsis criteria prior to implementation of an ED Sepsis Tracking Sheet
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ED Sepsis Tracking Sheet
2021
N/A
~200

Find a Location

Who is running the clinical trial?

Dartmouth-Hitchcock Medical CenterLead Sponsor
524 Previous Clinical Trials
2,543,145 Total Patients Enrolled
Harman Gill, MDPrincipal InvestigatorDartmouth-Hitchcock Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
JamaJournal
The Third International Consensus Definitions for Sepsis and Septic Shock (sepsis-3)
Singer, Mervyn, Clifford S. Deutschman, Christopher Warren Seymour, Manu Shankar-Hari, Djillali Annane, Michael Bauer, Rinaldo Bellomo, et al.. 2016. “The Third International Consensus Definitions for Sepsis and Septic Shock (sepsis-3)”. Jama. American Medical Association (AMA). doi:10.1001/jama.2016.0287.
VirulenceJournal
Epidemiology of Severe Sepsis
Mayr, Florian B, Sachin Yende, and Derek C Angus. 2013. “Epidemiology of Severe Sepsis”. Virulence. Informa UK Limited. doi:10.4161/viru.27372.
clinicaltrials.govStudy
ED Tracking Sheet Implementation
Harman S. Gill 2021. "ED Tracking Sheet Implementation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05213923.
~52 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top